Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684411 · ClinicalTrials.gov registry record · Phase 2
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00684411 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT00684411, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma.
Interventions
- DRUG Imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684411
The ClinicalTrials.gov registry entry for NCT00684411 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib mesylate is the first listed.
NCT00684411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684411 about?
NCT00684411 is a clinical study titled "Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma". The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help ...
What is the current status of trial NCT00684411?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00684411?
The interventions under investigation include: Imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00684411?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.